Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) has experienced a decline in its stock price by -0.34 compared to its previous closing price of 16.10. However, the company has seen a fall of -3.98% in its stock price over the last five trading days. fool.com reported 2025-03-24 that Data is abundant, if not overwhelming, on Wall Street. Between earnings season — the six-week period when a majority of S&P 500 companies unveil their quarterly operating results — and near-daily economic data releases, it can be easy to miss something important.
Is It Worth Investing in Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Right Now?
Company’s 36-month beta value is 0.70.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for TEVA is 1.15B, and currently, short sellers hold a 2.43% ratio of that float. The average trading volume of TEVA on March 24, 2025 was 12.10M shares.
TEVA’s Market Performance
TEVA’s stock has seen a -3.98% decrease for the week, with a -4.15% drop in the past month and a -24.32% fall in the past quarter. The volatility ratio for the week is 2.89%, and the volatility levels for the past 30 days are at 3.73% for Teva- Pharmaceutical Industries Ltd. ADR The simple moving average for the past 20 days is -0.46% for TEVA’s stock, with a -9.98% simple moving average for the past 200 days.
Analysts’ Opinion of TEVA
Many brokerage firms have already submitted their reports for TEVA stocks, with Argus repeating the rating for TEVA by listing it as a “Buy.” The predicted price for TEVA in the upcoming period, according to Argus is $20 based on the research report published on July 10, 2024 of the previous year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see TEVA reach a price target of $14. The rating they have provided for TEVA stocks is “Neutral” according to the report published on March 08th, 2024.
Piper Sandler gave a rating of “Overweight” to TEVA, setting the target price at $19 in the report published on February 12th of the previous year.
TEVA Trading at -9.62% from the 50-Day Moving Average
After a stumble in the market that brought TEVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.63% of loss for the given period.
Volatility was left at 3.73%, however, over the last 30 days, the volatility rate increased by 2.89%, as shares sank -4.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.36% lower at present.
During the last 5 trading sessions, TEVA fell by -4.01%, which changed the moving average for the period of 200-days by -3.55% in comparison to the 20-day moving average, which settled at $16.12. In addition, Teva- Pharmaceutical Industries Ltd. ADR saw -27.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TEVA starting from Daniell Richard, who sale 70,961 shares at the price of $15.91 back on Mar 05 ’25. After this action, Daniell Richard now owns 48,384 shares of Teva- Pharmaceutical Industries Ltd. ADR, valued at $1,128,642 using the latest closing price.
Hughes Eric A, the See “Remarks” of Teva- Pharmaceutical Industries Ltd. ADR, sale 15,174 shares at $15.73 during a trade that took place back on Mar 04 ’25, which means that Hughes Eric A is holding 8,077 shares at $238,757 based on the most recent closing price.
Stock Fundamentals for TEVA
Current profitability levels for the company are sitting at:
- -0.02 for the present operating margin
- 0.49 for the gross margin
The net margin for Teva- Pharmaceutical Industries Ltd. ADR stands at -0.1. The total capital return value is set at -0.01. Equity return is now at value -25.44, with -3.96 for asset returns.
Based on Teva- Pharmaceutical Industries Ltd. ADR (TEVA), the company’s capital structure generated 0.77 points at debt to capital in total, while cash flow to debt ratio is standing at 0.07. The debt to equity ratio resting at 3.36. The interest coverage ratio of the stock is -0.3.
Currently, EBITDA for the company is -303.0 million with net debt to EBITDA at 19.02. When we switch over and look at the enterprise to sales, we see a ratio of 2.01. The receivables turnover for the company is 5.41for trailing twelve months and the total asset turnover is 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.98.
Conclusion
In a nutshell, Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
